

Invitation to presentation of Magle Group's report for Q3 2022

Magle Chemoswed Holding AB (publ) will publish its interim report for Q3 2022 on Wednesday 9 November 2022 at 08:30 CET.

On the same day, Wednesday 9 November at 14:00 CEST, the company will hold a web conference hosted by CEO Justin Pierce and CFO Petra Jönsson Sjölin. After their presentation, there will be a Q&A session. The conference will be held in English. You can join the conference by computer or mobile device.

The number of participants is limited and we recommend signing up early to secure a spot. Please register at the following link:

<https://attendee.gotowebinar.com/register/1237311647916847374>

A recording of the web conference will afterwards be available on Magle Chemoswed's homepage maglechemoswed.com and on Västra Hamnen Corporate Finance's [YouTube channel](#).

Contacts

Megi Medzmariashvili, Legal Counsel, phone +46 (0)76 164 33 12, megi.medzmariashvili@maglechemoswed.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and <https://maglegroup.com/> and www.maglepharmaceut.com

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

[Invitation to presentation of Magle Group's report for Q3 2022](#)